findmyKOL
Clinical trialNCT03377790CompletedPhase 3Interventional

Cantharidin Application in Molluscum Patients-1

SponsorVerrica Pharmaceuticals Inc.Enrollment266Molluscum Contagiosum
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum. VP-102 will be applied once every 21 days for up to 4 applications, to treatable molluscum contagiosum (molluscum) lesions on subjects 2 years and older. Efficacy will be assessed as the proportion of subjects achieving complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Alabama Clinical Therapeutics

    Birmingham, Alabama, United States

  • Southeastern Pediatric Associates

    Dothan, Alabama, United States

  • Applied Research Center of Arkansas

    Little Rock, Arkansas, United States

  • Study Protocol, Inc.,

    Boynton Beach, Florida, United States

  • Skin Research Institute

    Coral Gables, Florida, United States

  • Asclepes Research Center

    Spring Hill, Florida, United States

  • Olympian Clinical Research

    Tampa, Florida, United States

  • Summit Dermatology

    Oakbrook Terrace, Illinois, United States

  • Clarkston Skin Research

    Clarkston, Michigan, United States

  • St Louis Children'S Hospital

    St Louis, Missouri, United States

  • Midwest Children'S Hospital

    Lincoln, Nebraska, United States

  • Kings County Hospital

    Brooklyn, New York, United States

  • University North Carolina Dermatology Center

    Chapel Hill, North Carolina, United States

  • the Pediatric Associates of Fairfield, Inc

    Fairfield, Ohio, United States

  • Holston Medical Group

    Bristol, Tennessee, United States

  • Arlington Research Center

    Arlington, Texas, United States

  • Center for Skin Research

    Houston, Texas, United States

  • Acrc Trials Plano Pediatrics

    Plano, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Mar 2018
Primary completion
26 Nov 2018
Completion
26 Nov 2018
Last update posted
11 Jan 2022
Registered enrollment
266
Registry id
NCT03377790
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.